{ "schemaVersion": "deck-intelligence.v1", "id": "019de074-6c10-759a-a503-c8b869115e9a", "slug": "3f9321c37d26dde2e5a75b53f195ef9c", "title": "Theravance Biopharma | Results Presentation Deck | 31 slides", "subtitle": "Theravance Biopharma · 2023-02", "author": "Theravance Biopharma", "date": "2023-02-01 00:00:00", "pageCount": 31, "kind": "conference-presentation", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de074-6c10-759a-a503-c8b869115e9a", "slug": "3f9321c37d26dde2e5a75b53f195ef9c", "title": "Theravance Biopharma | Results Presentation Deck | 31 slides", "rawTitle": "Theravance Biopharma | Results Presentation Deck | 31 slides", "authorId": "theravance-biopharma", "authorName": "Theravance Biopharma", "authorDisplay": "Theravance Biopharma", "kind": { "slug": "conference-presentation", "label": "Conference presentation" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2023-02__theravance-biopharma__results__3f9321c3.pdf", "sourceUrl": "https://www.slidebook.io/company/theravance-biopharma/presentation/3f9321c37d26dde2e5a75b53f195ef9c/", "sourceDate": "2023-02-27 00:00:00", "presentationDate": "2023-02-01 00:00:00", "ingestedAt": "2026-04-30 22:13:39.575075+00", "status": "ready", "pageCount": 31, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2023-02__theravance-biopharma__results__3f9321c3", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Results Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 31, "pagesIndexed": 31, "pagesWithImages": 31, "pagesWithMetadata": 31, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 159, "chartCount": 10, "metricSlides": 0, "toolMatches": 4, "documentToolMatches": 0, "frameworkMatches": 6, "arcMatches": 1, "beatMatches": 3, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null, "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "evidence": "The deck's focus on transformation and value creation, with a clear narrative arc", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:30:23.188679+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 5, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null, "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "from": 1, "name": "Current Reality (Pain)", "beatId": "10b7d6da-0202-4ef1-bc86-a1a55be52a9d", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Current Reality (Pain)", "slug": "transformation-tale-current-reality-pain", "status": "active", "canonId": "019dd9b8-2913-713f-b6ca-b978ac103400", "version": 1, "description": null }, "evidence": "Slides 1-5 set the stage for Theravance Biopharma's current state and challenges", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 19, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null, "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "from": 6, "name": "Future Vision (Gain)", "beatId": "d5542c65-e352-4522-bba8-062503c55e06", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Future Vision (Gain)", "slug": "transformation-tale-future-vision-gain", "status": "active", "canonId": "019dd9b8-29ef-708e-ada4-cb8260fa5139", "version": 1, "description": null }, "evidence": "Slides 6-19 present the company's vision and growth opportunities", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 25, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null, "categoryName": "Narrative & Transformation", "categorySlug": "narrative-transformation" }, "from": 20, "name": "The Bridge", "beatId": "a787cdd9-f5b1-4924-8826-e957eaed06be", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "The Bridge", "slug": "transformation-tale-the-bridge", "status": "active", "canonId": "019dd9b8-2a87-70ce-999e-f64c0e545f5d", "version": 1, "description": null }, "evidence": "Slides 20-25 provide a bridge between the current state and future vision", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 29, "from": 29, "loop": { "name": "21_before_after", "slug": "21-before-after", "status": "active", "bestFor": "Product demos, process improvements, ROI justification", "canonId": "019dd956-6e68-73fd-a295-fe90145c2da8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison", "familyLabel": null, "categoryName": "Comparison", "categorySlug": "comparison" }, "matchId": "7826842e-2e9b-4a36-849d-9c76e7c2f257", "evidence": "The before-after slide effectively communicates the benefits of Ampreloxetine treatment", "position": 0, "objective": "Illustrate the potential for broad symptomatic improvement for MSA patients", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:30:23.33131+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 7, "from": 7, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null, "categoryName": "Consulting Framework", "categorySlug": "consulting-framework" }, "matchId": "611002cb-ed2e-4777-af3b-18eb1fe10450", "evidence": "The slide presents YUPELRI's growth as a key achievement", "position": 1, "objective": "Highlight YUPELRI's growing net sales and hospital volume as a quick win", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:30:23.36757+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Thesis: Capital return", "slug": "capital-return", "status": "active", "bestFor": null, "canonId": "019df269-17fc-765c-9e3b-cb2463bc256d", "version": 1, "bodyDocId": "019df269-17d7-750a-895a-781a9e06829c", "description": "You argue the target is over-capitalised, has been chronically poor at", "familyLabel": "thesis-archetype", "categoryName": "Competitive", "categorySlug": "competitive" }, "agent": "storyteller", "layer": "slide", "agents": [ "storyteller" ], "matchId": "a359c05a-cf39-41e6-bdf3-1f4b16f713e5", "evidence": " $325 Million Capital Return Program", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:19:45.658631+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "81994016-c8c7-465d-a43d-88fe3948a979", "evidence": "table/data: Year, Royalties, Global Net Sales Equivalent, Milestone table for 2023-2026", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:19:45.808888+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Three Pillars", "slug": "three-pillars", "status": "active", "bestFor": null, "canonId": "019dd956-81ef-7455-a365-b234d95a6bbb", "version": 1, "bodyDocId": null, "description": "Three major supporting arguments that are MECE and address key concerns", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "e3969f62-d296-4b6b-aa87-7abced3fc107", "evidence": "Three distinct drivers of value over the near, mid, and long-term", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:19:45.884228+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "148dbfb1-622b-4ed8-a452-58aae51d61fe", "evidence": "2022: A Year of Transformation", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:19:46.148579+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "f4b4dfcb-57ac-41a7-aa86-d255b5a692e2", "evidence": "The timeline visualization represents the study phases and duration.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:06:34.885+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "gantt-chart" }, { "matchId": "7df6141a-c77e-460f-baeb-35c5f18c1278", "evidence": "The slide uses a structured table to compare product attributes against competitors.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:06:39.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "comparison_frame" }, { "matchId": "8faff2fb-f30f-42b7-9ff7-c001e81b4a4c", "evidence": "The slide uses a horizontal timeline to represent the phases of a clinical trial.", "framework": null, "confidence": 0.7, "extraction": { "at": "2026-05-02 12:06:35.077+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "gantt-chart" }, { "matchId": "d127c9d2-8533-4323-a2b9-c0beed8f58c3", "evidence": "The slide uses a directional arrow to link three distinct business drivers to a unified value creation outcome.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:06:35.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "frameworkName": "causal-chain" }, { "matchId": "c3e57869-e581-4b4a-a256-c08ece204561", "evidence": "The slide uses a funnel to represent the patient journey from diagnosis to treatment, followed by specific segment opportunities.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:06:42.45+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "frameworkName": "customer-journey-map" }, { "matchId": "52505bf8-cd47-42c1-ba84-9d77bb58ae2d", "evidence": "Contrasts 'Old' program with 'New' program to show strategic shift.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:06:49.826+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "frameworkName": "before-after-framing" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/CiSvF8ZIt7pQPiZYGpDPiyVcQNlmqbFewtp6cw2qpSg/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zZjkzMjFjMzdkMjZkZGUyZTVhNzViNTNmMTk1ZWY5Yy9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 45, "componentCount": 4, "textChars": 504, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:32.785+00", "seconds": 2.55, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/1", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-1", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.139, "w": 0.472, "x": 0.083, "y": 0.83 }, "kind": "disclaimer", "text": "THERAVANCE BIOPHARMA®, THERAVANCE®, the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. © 2023 Theravance Biopharma. All rights reserved.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:32.785+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "67752b88-30c2-4ce5-a067-d7e322c07782", "parentComponentId": null }, { "bbox": { "h": 0.306, "w": 0.458, "x": 0.078, "y": 0.148 }, "kind": "image", "text": "Theravance Biopharma Medicines That Make a Difference", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:32.785+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ae56fd75-dc8f-4fbe-a9b6-61160b0aef1e", "parentComponentId": null }, { "bbox": { "h": 0.042, "w": 0.292, "x": 0.083, "y": 0.718 }, "kind": "paragraph", "text": "February 27, 2023", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:32.785+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "11625d5a-8f3c-4ba8-991d-27d8b728d0fa", "parentComponentId": null }, { "bbox": { "h": 0.167, "w": 0.833, "x": 0.083, "y": 0.425 }, "kind": "title", "text": "Strategic Actions and Fourth Quarter / Full Year 2022 Financial Results and Business Update", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:32.785+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "322603e6-6c71-4a7c-9a04-d417204e084f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 1, "name": "Current Reality (Pain)", "beatId": "10b7d6da-0202-4ef1-bc86-a1a55be52a9d", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Current Reality (Pain)", "slug": "transformation-tale-current-reality-pain", "status": "active", "canonId": "019dd9b8-2913-713f-b6ca-b978ac103400", "version": 1, "description": null }, "evidence": "Slides 1-5 set the stage for Theravance Biopharma's current state and challenges", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/eJe7n-PxZsMzvHNGnnbiDmFL98rOpdn9ncpEHNSRnXI/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zZjkzMjFjMzdkMjZkZGUyZTVhNzViNTNmMTk1ZWY5Yy9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/P9ruqmQbRw6SXdxttuwWjf5w7gHjP82-Zv3Wae7-B8c/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zZjkzMjFjMzdkMjZkZGUyZTVhNzViNTNmMTk1ZWY5Yy9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/C2sKaZPxh6gzC8b0zHMIQSSKiLM2AL1vj95L5tudbvg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8zZjkzMjFjMzdkMjZkZGUyZTVhNzViNTNmMTk1ZWY5Yy9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 385, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:37.397+00", "seconds": 7.079, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/2", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-2", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.9, "x": 0.05, "y": 0.72 }, "kind": "disclaimer", "text": "Theravance Biopharma provides a non-GAAP profitability target in this presentation. Theravance Biopharma believes that the non-GAAP profitability target provides meaningful information...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.397+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "194ffdcc-1ffb-4710-8f7e-3605cc2c69eb", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "disclaimer", "text": "This presentation contains certain \"forward-looking\" statements as that term is defined in the Private Securities Litigation Reform Act of 1995...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.397+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a2a0a37c-986a-4646-b399-ae37c4cb2e08", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.4, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Forward-Looking Statements", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.397+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "62600892-bb75-4501-8512-e5c66456f474", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.25, "x": 0.05, "y": 0.67 }, "kind": "title", "text": "Non-GAAP Financial Measure", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.397+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "740e775f-03b2-43cb-bc5b-507604364b30", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 1, "name": "Current Reality (Pain)", "beatId": "10b7d6da-0202-4ef1-bc86-a1a55be52a9d", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Current Reality (Pain)", "slug": "transformation-tale-current-reality-pain", "status": "active", "canonId": "019dd9b8-2913-713f-b6ca-b978ac103400", "version": 1, "description": null }, "evidence": "Slides 1-5 set the stage for Theravance Biopharma's current state and challenges", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 3, "type": "setup", "function": "front_matter", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 14, "componentCount": 2, "textChars": 188, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:36.085+00", "seconds": 5.674, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/3", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-3", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.625, "w": 0.916, "x": 0.042, "y": 0.198 }, "kind": "table", "text": "Introduction and Overview: Rick E Winningham; Commercial and Development Update: Rhonda F. Farnum, Richard A. Graham; Financial Update: Aziz Sawaf; Closing Remarks: Rick E Winningham", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "226f05f1-ae22-4bc0-a7a0-7d9aab9a0969", "parentComponentId": null }, { "bbox": { "h": 0.122, "w": 0.176, "x": 0.048, "y": 0.048 }, "kind": "title", "text": "Agenda", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.085+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "89248a57-60b2-4955-8d85-9a211e7180a0", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 1, "name": "Current Reality (Pain)", "beatId": "10b7d6da-0202-4ef1-bc86-a1a55be52a9d", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Current Reality (Pain)", "slug": "transformation-tale-current-reality-pain", "status": "active", "canonId": "019dd9b8-2913-713f-b6ca-b978ac103400", "version": 1, "description": null }, "evidence": "Slides 1-5 set the stage for Theravance Biopharma's current state and challenges", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 4, "type": "setup", "title": "The slide uses a three-column layout to summarize corporate actions.", "function": "summarize", "rawType": "key_messages", "block": null, "metadata": { "slideType": "key_messages", "slideTypeCanon": { "name": "Key messages", "slug": "key_messages", "status": "active", "canonId": "019de52d-0712-703f-89f5-bda6688faf3f", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 88, "componentCount": 8, "textChars": 1031, "nDataPoints": 6, "notes": "The slide uses a three-column layout to summarize corporate actions.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:38.503+00", "seconds": 7.554, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/4", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-4", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.28, "x": 0.06, "y": 0.32 }, "kind": "list", "text": "Approved incremental $75M to existing $250M program initiated Sept’22, with goal to complete program by end of 2023. Repurchased $155M of stock to date, including $27M in 2023. $170M remains in capital return program; expected to complete by end of 2023", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:38.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0a500ad3-dbb0-414b-8e51-20928aee193b", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.28, "x": 0.36, "y": 0.32 }, "kind": "list", "text": "Prioritize resource allocation toward ampreloxetine Phase 3 study and YUPELRI® (revefenacin) PIFR-2 study. Discontinuing research activities, including stopping inhaled Janus kinase (JAK) inhibitor program. ~17% headcount reduction by end of Mar 2023", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:38.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "60810c1d-bb19-46c6-aa21-86a462eb2b67", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.28, "x": 0.66, "y": 0.32 }, "kind": "list", "text": "Appointed independent director Susannah Gray to Board of Directors. Part of ongoing commitment to board refreshment. Lead Independent Director William D. Young will not stand for re-election at 2023 AGM. Company will put forth proposal to declassify the Board of Directors over time at 2023 AGM", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:38.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "82d1a822-fdac-4557-b50c-0c03633f1e9b", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.28, "x": 0.36, "y": 0.2 }, "kind": "paragraph", "text": "Discontinuing Investments in Research", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:38.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2dbbe6dc-a461-4bdc-8e19-0debfc3f69b9", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.28, "x": 0.66, "y": 0.2 }, "kind": "paragraph", "text": "Board and Governance Evolution", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:38.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4ab925a8-88be-43a2-a28c-06a08e25fefd", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.28, "x": 0.06, "y": 0.2 }, "kind": "paragraph", "text": "Authorized $325M Capital Return Program", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:38.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ce491d53-9557-4fec-8670-ba3671b8ed16", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.02, "y": 0.92 }, "kind": "source-note", "text": "PIFR, peak inspiratory flow rate. AGM, Annual General Meeting – May 2, 2023", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:38.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6c43c5e9-d7df-42a5-9595-c0b6949f76c9", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Strategic Actions Focused on Continued Value Creation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:38.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d968b8cb-da3a-4b85-a80a-7979630c8ce8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 1, "name": "Current Reality (Pain)", "beatId": "10b7d6da-0202-4ef1-bc86-a1a55be52a9d", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Current Reality (Pain)", "slug": "transformation-tale-current-reality-pain", "status": "active", "canonId": "019dd9b8-2913-713f-b6ca-b978ac103400", "version": 1, "description": null }, "evidence": "Slides 1-5 set the stage for Theravance Biopharma's current state and challenges", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 5, "type": "resolution", "title": "The slide uses a three-column layout to categorize corporate objectives.", "function": "summarize", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 69, "componentCount": 5, "textChars": 1035, "nDataPoints": 4, "notes": "The slide uses a three-column layout to categorize corporate objectives.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:37.622+00", "seconds": 6.594, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/5", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-5", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.85, "x": 0.14, "y": 0.9 }, "kind": "disclaimer", "text": "1. Non-GAAP profit is expected to consist of GAAP income before taxes less share-based compensation expense and non-cash interest expense. 2. The first milestone payment, of $50.0 million, will be triggered if Royalty Pharma receives $240.0 million or more in royalty payments from GSK with respect to 2023 TRELEGY global net sales, which we would expect to occur in the event TRELEGY global net sales reach approximately $2.863 billion. MSA, multiple system atrophy; nOH, neurogenic orthostatic hypotension; PIFR, peak inspiratory flow rate.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.622+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2d9ae77a-047c-4ec7-b536-3a5ed02f41c6", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.28, "x": 0.68, "y": 0.375 }, "kind": "list", "text": "Expanded Capital Return Program to $325M, and expect to complete the remaining $170M this year; Generate Non-GAAP Profit in 2H'23; $50M potential milestone for TRELEGY Net Sales of ~$2.86B", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.622+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2a8d8fb5-67b5-4903-acd0-ba7fba7fac4c", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.28, "x": 0.37, "y": 0.375 }, "kind": "list", "text": "Initiate Phase 3 CYPRESS trial in MSA patients with symptomatic nOH in Q1'23; Submit orphan drug designation request in early 2023", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.622+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5e732b86-2112-40ee-afba-07fca2500b8a", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.28, "x": 0.06, "y": 0.375 }, "kind": "list", "text": "Continue YUPELRI Net Sales growth by executing on targeted strategies to capture sizeable niche market; Complete PIFR-2 study and provide top-line results in 2H'23", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.622+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b305ca37-b9b5-4708-b290-df5f5f4b6d62", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.25, "x": 0.05, "y": 0.06 }, "kind": "title", "text": "2023 Targets", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.622+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6185f13b-5178-49f3-bc14-0ea4acd92b03", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 1, "name": "Current Reality (Pain)", "beatId": "10b7d6da-0202-4ef1-bc86-a1a55be52a9d", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Current Reality (Pain)", "slug": "transformation-tale-current-reality-pain", "status": "active", "canonId": "019dd9b8-2913-713f-b6ca-b978ac103400", "version": 1, "description": null }, "evidence": "Slides 1-5 set the stage for Theravance Biopharma's current state and challenges", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 6, "type": "setup", "function": "summarize", "rawType": "key_messages", "block": null, "metadata": { "slideType": "key_messages", "slideTypeCanon": { "name": "Key messages", "slug": "key_messages", "status": "active", "canonId": "019de52d-0712-703f-89f5-bda6688faf3f", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 27, "componentCount": 3, "textChars": 249, "nDataPoints": 2, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 15:31:18.905+00", "seconds": 2.068, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/6", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-6", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.07, "w": 0.12, "x": 0.015, "y": 0.91 }, "kind": "image", "text": "Theravance Biopharma logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:18.905+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d3670dd-b41c-49aa-ae04-11d6bf74bf41", "parentComponentId": null }, { "bbox": { "w": 0.25, "x": 0.25, "y": 0.16 }, "kind": "image", "text": "YUPELRI logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:18.905+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "621fb386-a189-459f-a9b6-7d87b85a9c60", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.85, "x": 0.07, "y": 0.53 }, "kind": "list", "text": "FDA-approved for maintenance treatment of COPD\nFirst and only once-daily, LAMA (long-acting muscarinic agent) nebulized maintenance medicine for COPD\nCo-promotion agreement with VIATRISTM (35% / 65% Profit Share)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 15:31:18.905+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5098584d-1b41-4a0c-9012-c9e93a96e324", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 19, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 6, "name": "Future Vision (Gain)", "beatId": "d5542c65-e352-4522-bba8-062503c55e06", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Future Vision (Gain)", "slug": "transformation-tale-future-vision-gain", "status": "active", "canonId": "019dd9b8-29ef-708e-ada4-cb8260fa5139", "version": 1, "description": null }, "evidence": "Slides 6-19 present the company's vision and growth opportunities", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 7, "type": "analysis", "title": "The slide uses two bar charts to illustrate growth trends over five quarters.", "function": "analyze_data", "rawType": "kpi_overview", "block": null, "metadata": { "slideType": "kpi_overview", "slideTypeCanon": { "name": "KPI overview (contrarian)", "slug": "kpi_overview", "status": "active", "canonId": "019de52d-11d5-7328-b1d1-5368a03e7796", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 65, "componentCount": 6, "textChars": 369, "nDataPoints": 10, "notes": "The slide uses two bar charts to illustrate growth trends over five quarters.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:33.866+00", "seconds": 2.755, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/7", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-7", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.38, "x": 0.55, "y": 0.75 }, "kind": "callout", "text": "53% year-over-year volume growth in 2022", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:33.866+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2f5d4838-e335-42da-a992-ffcc84b17a00", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.38, "x": 0.08, "y": 0.75 }, "kind": "callout", "text": "25% year-over-year net sales growth in 2022", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:33.866+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7f103666-5e06-4824-873a-af4b7afd679d", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.45, "x": 0.05, "y": 0.2 }, "kind": "chart", "text": "Net sales increased 27% Q4'22 vs. Q4'21", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:33.866+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "43b6cb0b-3d6d-44fa-824e-a6be65510ca7", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.45, "x": 0.52, "y": 0.2 }, "kind": "chart", "text": "Hospital doses sold increased 47% Q4'22 vs. Q4'21", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:33.866+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bd8cb613-92ee-4e4f-beeb-37bfc07b2c5a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.9 }, "kind": "source-note", "text": "Source: IQVIA DDD, HDS, VA and Non-Reporting Hospital through 12/31/2022. See TBPH 10K filed February 28, 2022 for greater detail re TBPH implied 35%.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:33.866+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f0e845af-eebc-465c-9496-0052bf51eba6", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "YUPELRI® | Growing Net Sales and Hospital Volume", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:33.866+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5ee5ad47-3461-4ca3-96db-bef1c102ad17", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 19, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 6, "name": "Future Vision (Gain)", "beatId": "d5542c65-e352-4522-bba8-062503c55e06", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Future Vision (Gain)", "slug": "transformation-tale-future-vision-gain", "status": "active", "canonId": "019dd9b8-29ef-708e-ada4-cb8260fa5139", "version": 1, "description": null }, "evidence": "Slides 6-19 present the company's vision and growth opportunities", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 7, "from": 7, "loop": { "name": "47_quick_win_big_bet", "slug": "47-quick-win-big-bet", "status": "active", "bestFor": "Transformation planning, 100-day plans, resource allocation", "canonId": "019dd956-790d-708d-983e-ef9bbc68f741", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap", "description": "Separate initiatives into immediate wins and longer-term strategic bets", "familyLabel": null }, "matchId": "611002cb-ed2e-4777-af3b-18eb1fe10450", "evidence": "The slide presents YUPELRI's growth as a key achievement", "position": 1, "objective": "Highlight YUPELRI's growing net sales and hospital volume as a quick win", "confidence": 0.6, "extraction": { "at": "2026-07-16 22:30:23.36757+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "analysis", "title": "The slide uses a line chart for hospital share and a combo bar/line chart for community share to illustrate market penetration.", "function": "analyze_data", "rawType": "kpi_overview", "block": null, "metadata": { "slideType": "kpi_overview", "slideTypeCanon": { "name": "KPI overview (contrarian)", "slug": "kpi_overview", "status": "active", "canonId": "019de52d-11d5-7328-b1d1-5368a03e7796", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 83, "componentCount": 7, "textChars": 681, "nDataPoints": 24, "notes": "The slide uses a line chart for hospital share and a combo bar/line chart for community share to illustrate market penetration.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:38.313+00", "seconds": 7.09, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/8", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-8", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.45, "x": 0.52, "y": 0.25 }, "kind": "chart", "text": "Community Market Share with TRx", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:38.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "84c1892a-0359-4bf4-9305-7e965c209085", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.45, "x": 0.05, "y": 0.25 }, "kind": "chart", "text": "Hospital Market Share", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:38.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b5be70bd-032e-4149-8155-1192df8980b5", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.45, "x": 0.05, "y": 0.78 }, "kind": "paragraph", "text": "Most patients who receive YUPELRI® in the hospital are discharged with an Rx", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:38.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "be326c14-3918-4b71-89c9-ad65bf0e9921", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.45, "x": 0.52, "y": 0.78 }, "kind": "paragraph", "text": "TRx volume represents retail only which is typically 33% of Retail + DME Reported DME volume, while lagged, typically follows Retail volume trends", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:38.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d5bae3b6-f807-4f8e-852f-5a589868b993", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.9 }, "kind": "source-note", "text": "1. Joint VTRS/TBPH Market Research. * Hospital LA-NEB Market Share - IQVIA DDD through 12/31/2022. †Community LA-NEB Market Share includes Retail + DME / Med B FFS through Nov'22 ‡Retail TRx Volume - Symphony Health METYS Prescription Dashboard through 12/31/2022.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:38.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ef1a68c6-5068-46cf-bffc-7856a916e375", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.13 }, "kind": "title", "text": "Hospital share dropped slightly due to largest Q/Q growth in market volume since YUPELRI launch", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:38.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6f2a143c-8fc1-479e-816a-e3e8f377804b", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "YUPELRI® Hospital Sales and Community TRx Trends", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:38.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "749bae07-b319-4579-94a2-eb4a16783dd5", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 19, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 6, "name": "Future Vision (Gain)", "beatId": "d5542c65-e352-4522-bba8-062503c55e06", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Future Vision (Gain)", "slug": "transformation-tale-future-vision-gain", "status": "active", "canonId": "019dd9b8-29ef-708e-ada4-cb8260fa5139", "version": 1, "description": null }, "evidence": "Slides 6-19 present the company's vision and growth opportunities", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 9, "type": "setup", "title": "The slide outlines a clinical trial methodology using a timeline-based process flow.", "function": "present_framework", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 5, "textChars": 577, "nDataPoints": 1, "notes": "The slide outlines a clinical trial methodology using a timeline-based process flow.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:34.885+00", "seconds": 3.373, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/9", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-9", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.9, "x": 0.05, "y": 0.25 }, "kind": "diagram", "text": "Study timeline showing Run-in, Randomization, 12-week treatment period, and Results.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.885+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9463c363-c5dd-469a-ac06-33aa84275b25", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.9 }, "kind": "disclaimer", "text": "Phase 4, Randomized, Double-Blind, Parallel-Group Study in Adults With Severe-to-Very-Severe COPD and Suboptimal Inspiratory Flow Rate. *Dry powder inhaler (Spiriva® HandiHaler®). FEV1, forced expiratory volume in 1 second; PIFR, peak inspiratory flow rate.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.885+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6fe1d95c-84f7-41aa-8107-7bba832dd024", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.5, "x": 0.45, "y": 0.6 }, "kind": "list", "text": "Endpoints: Primary (Change from baseline in trough FEV1), Key secondary (Trough overall treatment effect on FEV1)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.885+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5aa5e562-400c-40c5-b422-14789c2aeee0", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.4, "x": 0.05, "y": 0.6 }, "kind": "list", "text": "Sample size: N = Up to 488; Top-line results 2H'23", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.885+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cf3f6bdd-fa51-436c-9cbb-770a84a5dc88", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "YUPELRI®: Phase 4 Randomized, Double-Blind, Parallel-Group Study (PIFR-2)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.885+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d72de156-49f8-401e-ac8d-f6628aaf7e2b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "f4b4dfcb-57ac-41a7-aa86-d255b5a692e2", "evidence": "The timeline visualization represents the study phases and duration.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:06:34.885+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "gantt-chart" } ], "arcBeats": [ { "to": 19, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 6, "name": "Future Vision (Gain)", "beatId": "d5542c65-e352-4522-bba8-062503c55e06", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Future Vision (Gain)", "slug": "transformation-tale-future-vision-gain", "status": "active", "canonId": "019dd9b8-29ef-708e-ada4-cb8260fa5139", "version": 1, "description": null }, "evidence": "Slides 6-19 present the company's vision and growth opportunities", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 10, "type": "setup", "function": "establish_context", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "sparse", "densityScore": 18, "componentCount": 3, "textChars": 171, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:33.932+00", "seconds": 2.367, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/10", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-10", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.09, "w": 0.765, "x": 0.068, "y": 0.588 }, "kind": "paragraph", "text": "For symptomatic neurogenic orthostatic hypotension (nOH) in multiple system atrophy (MSA) patients", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:33.932+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b4d67338-3a7a-4cf4-b2c6-033e252155a4", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.765, "x": 0.068, "y": 0.475 }, "kind": "paragraph", "text": "Investigational once-daily norepinephrine reuptake inhibitor", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:33.932+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d7b4c5f3-cc8e-4c57-b825-84fe01c61bd2", "parentComponentId": null }, { "bbox": { "h": 0.085, "w": 0.371, "x": 0.068, "y": 0.295 }, "kind": "title", "text": "Ampreloxetine", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:33.932+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7e2be843-a228-40c2-9088-1736d43b8eaf", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 19, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 6, "name": "Future Vision (Gain)", "beatId": "d5542c65-e352-4522-bba8-062503c55e06", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Future Vision (Gain)", "slug": "transformation-tale-future-vision-gain", "status": "active", "canonId": "019dd9b8-29ef-708e-ada4-cb8260fa5139", "version": 1, "description": null }, "evidence": "Slides 6-19 present the company's vision and growth opportunities", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 11, "type": "setup", "title": "The slide uses a two-part structure: a top section for market sizing/segmentation and a bottom section for a competitive product comparison table.", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "dense", "densityScore": 66, "componentCount": 6, "textChars": 412, "nDataPoints": 6, "notes": "The slide uses a two-part structure: a top section for market sizing/segmentation and a bottom section for a competitive product comparison table.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:39.962+00", "seconds": 8.385, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/11", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-11", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.9 }, "kind": "disclaimer", "text": "Reflects Theravance Biopharma's expectations for ampreloxetine based on clinical trial data to date.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:39.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e19f74aa-bd71-44d8-95d0-9146f90e7603", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.65, "y": 0.25 }, "kind": "list", "text": "35K – 45K MSA patients with nOH symptoms", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:39.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4b0f59ae-06f3-4352-abfc-ceb3cb016b3f", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.05, "y": 0.25 }, "kind": "list", "text": "~50K MSA patients in U.S. (considered orphan disease)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:39.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7660e26f-c0d9-4cc0-8b88-ce1a89ac385d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.35, "y": 0.25 }, "kind": "list", "text": "70%-90% of MSA patients experience nOH symptoms", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:39.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e00e4b76-9a42-4123-bd7e-427f4701da56", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.75, "x": 0.15, "y": 0.55 }, "kind": "table", "text": "Comparison table of Droxidopa, Midodrine, and Ampreloxetine across Indication, Efficacy/Durability, Dosing, and Safety.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:39.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d6975f3b-4908-4cb5-b09f-d108137b5c28", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "New Era in Treating MSA Symptoms: Product Positioning", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:39.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5050fd0f-3a68-4ae6-bace-b6d3d3c382d3", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "7df6141a-c77e-460f-baeb-35c5f18c1278", "evidence": "The slide uses a structured table to compare product attributes against competitors.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:06:39.962+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "comparison_frame" } ], "arcBeats": [ { "to": 19, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 6, "name": "Future Vision (Gain)", "beatId": "d5542c65-e352-4522-bba8-062503c55e06", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Future Vision (Gain)", "slug": "transformation-tale-future-vision-gain", "status": "active", "canonId": "019dd9b8-29ef-708e-ada4-cb8260fa5139", "version": 1, "description": null }, "evidence": "Slides 6-19 present the company's vision and growth opportunities", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 12, "type": "resolution", "title": "The chart is a forest plot showing LS Mean differences with 95% confidence intervals.", "function": "analyze_data", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 73, "componentCount": 6, "textChars": 565, "nDataPoints": 11, "notes": "The chart is a forest plot showing LS Mean differences with 95% confidence intervals.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:34.298+00", "seconds": 2.644, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/12", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-12", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.5, "x": 0.05, "y": 0.35 }, "kind": "chart", "text": "Forest plot of Study 0170 OHQ Questionnaire Scores", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.298+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1b8f5fc3-12ed-421d-a49e-f118fe3cdb70", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.35, "x": 0.6, "y": 0.3 }, "kind": "list", "text": "Once-daily dosing, single 10mg tablet; Low dosing frequency improves compliance; Decreases caregiver burden", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.298+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "84bcd6d7-76f6-4c29-ba48-2954a69662be", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.35, "x": 0.6, "y": 0.7 }, "kind": "list", "text": "Available to patients with supine hypertension; Can be taken anytime of day/night; Potential to be combined with other drugs", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.298+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "868f48ae-61ef-4dea-a269-d248b6369be9", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.8 }, "kind": "paragraph", "text": "Improvement in activities of daily living that require walking and standing for a short time which could favorably impact caregiver burden", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.298+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a21c4d10-608c-46e3-99a8-38a83ecab057", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.9 }, "kind": "source-note", "text": "Reflects Theravance Biopharma's expectations... Data on file. 1. Data from MSA patients at week 6...", "attrs": { "numbered": true }, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.298+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a079df18-6784-4666-905f-fa12f6fef18a", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "The Unique Benefits of Ampreloxetine Treatment", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.298+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9db35ea5-bbd7-4724-a1d1-4a5b5b9d9540", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 19, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 6, "name": "Future Vision (Gain)", "beatId": "d5542c65-e352-4522-bba8-062503c55e06", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Future Vision (Gain)", "slug": "transformation-tale-future-vision-gain", "status": "active", "canonId": "019dd9b8-29ef-708e-ada4-cb8260fa5139", "version": 1, "description": null }, "evidence": "Slides 6-19 present the company's vision and growth opportunities", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 13, "type": "appendix", "title": "The slide uses a timeline-based process diagram to illustrate the clinical trial structure.", "function": "present_framework", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "present_framework", "functionCanon": { "name": "Present framework", "slug": "present_framework", "status": "active", "canonId": "019de52d-1403-7667-9100-d2ac6709f750", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 6, "textChars": 476, "nDataPoints": 2, "notes": "The slide uses a timeline-based process diagram to illustrate the clinical trial structure.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:35.077+00", "seconds": 3.286, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/13", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-13", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.9, "x": 0.05, "y": 0.45 }, "kind": "diagram", "text": "Clinical trial timeline showing entry, open-label phase, randomization, double-blind RWD phase, and results.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.077+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "90e34c43-2eee-4f5b-8a45-728ea7d7a246", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.1, "x": 0.85, "y": 0.75 }, "kind": "metric", "text": "n~60 Completers", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.077+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10f5bb56-f3a8-4f11-8ee0-10cf80a5500d", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.1, "x": 0.18, "y": 0.75 }, "kind": "metric", "text": "n~100 To be enrolled", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.077+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fe025a23-f3b3-4def-9629-77081232699b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.9 }, "kind": "source-note", "text": "MSA, multiple system atrophy; nOH, neurogenic orthostatic hypotension; OHSA, orthostatic hypotension symptom assessment; RWD, randomized withdrawal design.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.077+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7748ac25-0bc0-4cf5-8fc6-96295f6373a9", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.05, "y": 0.25 }, "kind": "subtitle", "text": "Study 0197 (CYPRESS): Phase 3 randomized withdrawal study in patients with MSA. Primary endpoint: change in OHSA composite score", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.077+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c264c3a-5c65-4392-b2ef-7e9a2bd5f5a0", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.9, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "Offering Hope to MSA Patients with Symptomatic nOH", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.077+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "baafdd0b-203f-45f5-982f-495b1575338a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "8faff2fb-f30f-42b7-9ff7-c001e81b4a4c", "evidence": "The slide uses a horizontal timeline to represent the phases of a clinical trial.", "framework": null, "confidence": 0.7, "extraction": { "at": "2026-05-02 12:06:35.077+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "gantt-chart" } ], "arcBeats": [ { "to": 19, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 6, "name": "Future Vision (Gain)", "beatId": "d5542c65-e352-4522-bba8-062503c55e06", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Future Vision (Gain)", "slug": "transformation-tale-future-vision-gain", "status": "active", "canonId": "019dd9b8-29ef-708e-ada4-cb8260fa5139", "version": 1, "description": null }, "evidence": "Slides 6-19 present the company's vision and growth opportunities", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 14, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 1, "componentCount": 1, "textChars": 16, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:33.521+00", "seconds": 1.573, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/14", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-14", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.088, "w": 0.412, "x": 0.068, "y": 0.385 }, "kind": "title", "text": "Financial Update", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:33.521+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f2f9142a-a2be-4fd1-a22c-8de520dbc40a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 19, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 6, "name": "Future Vision (Gain)", "beatId": "d5542c65-e352-4522-bba8-062503c55e06", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Future Vision (Gain)", "slug": "transformation-tale-future-vision-gain", "status": "active", "canonId": "019dd9b8-29ef-708e-ada4-cb8260fa5139", "version": 1, "description": null }, "evidence": "Slides 6-19 present the company's vision and growth opportunities", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 15, "type": "setup", "function": "summarize", "rawType": "kpi_overview", "block": null, "metadata": { "slideType": "kpi_overview", "slideTypeCanon": { "name": "KPI overview (contrarian)", "slug": "kpi_overview", "status": "active", "canonId": "019de52d-11d5-7328-b1d1-5368a03e7796", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 5, "textChars": 358, "nDataPoints": 6, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:34.215+00", "seconds": 2.209, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/15", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-15", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.85, "x": 0.08, "y": 0.75 }, "kind": "callout", "text": "$170M remains in capital return program; expected to complete by end of 2023", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.215+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10196b00-b87a-40eb-815c-9d24c7b331ce", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.85, "x": 0.08, "y": 0.65 }, "kind": "callout", "text": "~50% (or ~$155M) of $325M capital return program completed as of 2/27/23", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.215+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9b0f587d-e4d3-4c50-823f-6e9e7bafb9f2", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.34, "y": 0.42 }, "kind": "list", "text": "~$33M completed in Dec’22; ~$27M completed in 2023, through 2/27/23", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.215+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "50566c52-8d1d-4947-acda-cf884c9fd933", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.6, "x": 0.34, "y": 0.25 }, "kind": "list", "text": "~$95M: Purchased GSK's equity stake in Theravance (Sep’22) and completed Dutch auction tender offer (Nov’22)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.215+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8b07df40-976d-42fa-b2b0-4b918fde1081", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.45, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "$325 Million Capital Return Program", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:34.215+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c2a343a4-8e52-42f7-8bc7-6e04d3a1bd47", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Thesis: Capital return", "slug": "capital-return", "status": "active", "bestFor": null, "canonId": "019df269-17fc-765c-9e3b-cb2463bc256d", "version": 1, "bodyDocId": "019df269-17d7-750a-895a-781a9e06829c", "description": "You argue the target is over-capitalised, has been chronically poor at", "familyLabel": "thesis-archetype", "categoryName": "Competitive", "categorySlug": "competitive" }, "agent": "storyteller", "layer": "slide", "agents": [ "storyteller" ], "matchId": "a359c05a-cf39-41e6-bdf3-1f4b16f713e5", "evidence": " $325 Million Capital Return Program", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:19:45.658631+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 15, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 19, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 6, "name": "Future Vision (Gain)", "beatId": "d5542c65-e352-4522-bba8-062503c55e06", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Future Vision (Gain)", "slug": "transformation-tale-future-vision-gain", "status": "active", "canonId": "019dd9b8-29ef-708e-ada4-cb8260fa5139", "version": 1, "description": null }, "evidence": "Slides 6-19 present the company's vision and growth opportunities", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 16, "type": "setup", "title": "The slide highlights specific cash flow activities like tax payments and share buybacks.", "function": "summarize", "rawType": "kpi_overview", "block": null, "metadata": { "slideType": "kpi_overview", "slideTypeCanon": { "name": "KPI overview (contrarian)", "slug": "kpi_overview", "status": "active", "canonId": "019de52d-11d5-7328-b1d1-5368a03e7796", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 34, "componentCount": 4, "textChars": 176, "nDataPoints": 5, "notes": "The slide highlights specific cash flow activities like tax payments and share buybacks.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:35.059+00", "seconds": 2.72, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/16", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-16", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.3, "x": 0.14, "y": 0.9 }, "kind": "source-note", "text": "1. Cash, cash equivalents and marketable securities. SBC, Share-based compensation.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.059+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "41426b13-60ff-41fe-8cb2-a5d6865e41fa", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.9, "x": 0.05, "y": 0.24 }, "kind": "table", "text": "Financial metrics table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "KPI table", "slug": "kpi", "status": "active", "canonId": "019de52d-0324-7799-a84e-d0885a8ad400", "version": 1, "description": null }, "framework": null }, "subkind": "kpi", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.059+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "98f66d67-663d-45b1-9008-807a878ae522", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.13 }, "kind": "title", "text": "Beginning 2023 from a position of strength", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.059+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cd298270-829c-4a92-baac-15dc60ed1601", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.4, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Q4 2022 Financial Highlights", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.059+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a509ec5d-b0b9-4ea0-9230-0c85fda52fae", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 19, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 6, "name": "Future Vision (Gain)", "beatId": "d5542c65-e352-4522-bba8-062503c55e06", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Future Vision (Gain)", "slug": "transformation-tale-future-vision-gain", "status": "active", "canonId": "019dd9b8-29ef-708e-ada4-cb8260fa5139", "version": 1, "description": null }, "evidence": "Slides 6-19 present the company's vision and growth opportunities", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 17, "type": "analysis", "title": "The chart shows a significant reduction in operating expenses from 2020 to 2023 guidance.", "function": "analyze_data", "rawType": "kpi_overview", "block": null, "metadata": { "slideType": "kpi_overview", "slideTypeCanon": { "name": "KPI overview (contrarian)", "slug": "kpi_overview", "status": "active", "canonId": "019de52d-11d5-7328-b1d1-5368a03e7796", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 81, "componentCount": 7, "textChars": 663, "nDataPoints": 12, "notes": "The chart shows a significant reduction in operating expenses from 2020 to 2023 guidance.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:36.004+00", "seconds": 3.54, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/17", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-17", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.48, "x": 0.48, "y": 0.25 }, "kind": "chart", "text": "Operating Expenses (Excluding Share-Based Comp & Restructuring Expenses) ($M)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Stacked bar chart", "slug": "bar-stacked", "status": "active", "canonId": "019de52c-feec-74bf-9028-15b74f84f0a7", "version": 1, "description": null }, "framework": null }, "subkind": "bar-stacked", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.004+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8e6ada96-7044-4ab8-87b0-41e050942f68", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.4, "x": 0.05, "y": 0.42 }, "kind": "list", "text": "Guidance Excludes: Non-cash share-based compensation; One-time severance and termination costs associated with 2023 headcount reduction: Expected to be $1M - $2M in Q1'23", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.004+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2d9c7027-8cc4-4805-a2a1-13fbea429a6d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.05, "y": 0.25 }, "kind": "list", "text": "2023 OPEX Guidance Range: R&D: $35M - $45M; SG&A: $45M - $55M", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.004+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "58e5beae-469f-423a-8b5c-34a64d681b8e", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.4, "x": 0.05, "y": 0.67 }, "kind": "list", "text": "Share-Based Compensation: Expected to decline materially in 2023 vs. 2022", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.004+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "defb05b5-7bfd-4de2-b497-ddf04099e5a8", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.9 }, "kind": "source-note", "text": "1. Non-GAAP profit is expected to consist of GAAP income before taxes less share-based compensation expense and non-cash interest expense; see the section titled \"Non-GAAP Financial Measure\" for more information.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.004+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "959dfe47-1f8f-4811-936a-70bd12f33c43", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.12 }, "kind": "title", "text": "Expected to generate non-GAAP Profit in 2H 2023", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.004+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "34c104dc-1d0f-4fdb-a016-54a33416b450", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.4, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "2023 Financial Guidance", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.004+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0927dbb7-767f-43f6-b3b8-5aa34b06beaf", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 19, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 6, "name": "Future Vision (Gain)", "beatId": "d5542c65-e352-4522-bba8-062503c55e06", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Future Vision (Gain)", "slug": "transformation-tale-future-vision-gain", "status": "active", "canonId": "019dd9b8-29ef-708e-ada4-cb8260fa5139", "version": 1, "description": null }, "evidence": "Slides 6-19 present the company's vision and growth opportunities", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 18, "type": "analysis", "title": "The table displays projected royalties and milestones for 2023-2026. The slide highlights the transition of royalty payments back to Theravance Biopharma starti", "function": "analyze_data", "rawType": "kpi_overview", "block": null, "metadata": { "slideType": "kpi_overview", "slideTypeCanon": { "name": "KPI overview (contrarian)", "slug": "kpi_overview", "status": "active", "canonId": "019de52d-11d5-7328-b1d1-5368a03e7796", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 70, "componentCount": 6, "textChars": 440, "nDataPoints": 24, "notes": "The table displays projected royalties and milestones for 2023-2026. The slide highlights the transition of royalty payments back to Theravance Biopharma starting in 2029.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:35.463+00", "seconds": 2.902, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/18", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-18", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.35, "x": 0.6, "y": 0.42 }, "kind": "list", "text": "Ex-US royalties return Jul. 1, 2029; US royalties return after Jan. 1, 2031; Paid directly from Royalty Pharma", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.463+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "67e477f2-c9e5-433b-8998-11b3210e4392", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.45, "x": 0.04, "y": 0.8 }, "kind": "metric", "text": "Q4 Net Sales of $537M | FY 2022 Net Sales of $2.1B", "attrs": null, "canon": { "kind": { "name": "Metric", "slug": "metric", "status": "active", "canonId": "019de52c-f923-73bf-8081-d0b1a8c5264d", "version": 1, "description": "Big-number or KPI value." }, "tool": null, "subkind": { "name": "Big number", "slug": "big-number", "status": "active", "canonId": "019de52c-fc70-70c8-b965-0584548a9204", "version": 1, "description": null }, "framework": null }, "subkind": "big-number", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.463+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f6994aad-d584-4506-8c98-63f1c01592ce", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.14, "y": 0.9 }, "kind": "source-note", "text": "1. If both milestones are achieved in a given year... 4. Source: Bloomberg", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.463+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "01d46c1e-51b2-4563-b978-76662af1c0e7", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.9, "x": 0.04, "y": 0.12 }, "kind": "subtitle", "text": "GSK's TRELEGY ELLIPTA (FF/UMEC/VI): First and only once-daily single inhaler triple therapy", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.463+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0e4f477e-4f1e-4afc-b25b-d860ebb5b5ef", "parentComponentId": null }, { "bbox": { "h": 0.42, "w": 0.38, "x": 0.09, "y": 0.385 }, "kind": "table", "text": "Year, Royalties, Global Net Sales Equivalent, Milestone table for 2023-2026", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.463+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7cd1c2cd-2b31-4bec-aa8c-a3d1be7cc729", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.65, "x": 0.04, "y": 0.05 }, "kind": "title", "text": "TRELEGY ELLIPTA Milestones and Royalties", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.463+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ed56179d-0264-4b54-9969-374046368be3", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "81994016-c8c7-465d-a43d-88fe3948a979", "evidence": "table/data: Year, Royalties, Global Net Sales Equivalent, Milestone table for 2023-2026", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:19:45.808888+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 19, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 6, "name": "Future Vision (Gain)", "beatId": "d5542c65-e352-4522-bba8-062503c55e06", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Future Vision (Gain)", "slug": "transformation-tale-future-vision-gain", "status": "active", "canonId": "019dd9b8-29ef-708e-ada4-cb8260fa5139", "version": 1, "description": null }, "evidence": "Slides 6-19 present the company's vision and growth opportunities", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 19, "type": "setup", "title": "Uses a curved arrow diagram to represent a progression of value drivers.", "function": "summarize", "rawType": "key_messages", "block": null, "metadata": { "slideType": "key_messages", "slideTypeCanon": { "name": "Key messages", "slug": "key_messages", "status": "active", "canonId": "019de52d-0712-703f-89f5-bda6688faf3f", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 74, "componentCount": 8, "textChars": 507, "nDataPoints": 0, "notes": "Uses a curved arrow diagram to represent a progression of value drivers.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:35.955+00", "seconds": 3.365, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/19", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-19", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.7, "x": 0.15, "y": 0.8 }, "kind": "callout", "text": "Positioned to create value from a foundation of financial strength", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f9b2e48f-ec20-4747-87cf-cb960035a397", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.9, "x": 0.05, "y": 0.35 }, "kind": "diagram", "text": "Curved arrow showing progression from YUPELRI to Ampreloxetine to TRELEGY", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "90b6fb60-a469-435a-a65e-1e8279dd0749", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.38, "y": 0.55 }, "kind": "paragraph", "text": "Potential to offer a unique, first in class treatment benefit", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0cd9c221-0eaa-45f1-8f3f-b6553e34d2e5", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.2, "x": 0.1, "y": 0.65 }, "kind": "paragraph", "text": "Substantial opportunity for further growth", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3e158ab0-2c25-4cfd-875a-bf1cd7aa7cee", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.65, "y": 0.45 }, "kind": "paragraph", "text": "Retained future value of TRELEGY in milestones and certain outer year royalties", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "901324af-d202-4249-9975-392c1fc97b88", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.14, "y": 0.91 }, "kind": "source-note", "text": "MSA, multiple system atrophy; nOH, neurogenic orthostatic hypotension.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9c52f715-d3fc-478a-84c4-69200e2534a0", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.15, "y": 0.18 }, "kind": "title", "text": "Three distinct drivers of value over the near, mid, and long-term", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e44b644d-7840-4c9f-99d9-f08ddd570da4", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Theravance Biopharma: Positioned for Value Creation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b738ed32-1c43-40ca-bae1-2c7df455af67", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Three Pillars", "slug": "three-pillars", "status": "active", "bestFor": null, "canonId": "019dd956-81ef-7455-a365-b234d95a6bbb", "version": 1, "bodyDocId": null, "description": "Three major supporting arguments that are MECE and address key concerns", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "e3969f62-d296-4b6b-aa87-7abced3fc107", "evidence": "Three distinct drivers of value over the near, mid, and long-term", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:19:45.884228+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "d127c9d2-8533-4323-a2b9-c0beed8f58c3", "evidence": "The slide uses a directional arrow to link three distinct business drivers to a unified value creation outcome.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:06:35.955+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "frameworkName": "causal-chain" } ], "arcBeats": [ { "to": 19, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 6, "name": "Future Vision (Gain)", "beatId": "d5542c65-e352-4522-bba8-062503c55e06", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "Future Vision (Gain)", "slug": "transformation-tale-future-vision-gain", "status": "active", "canonId": "019dd9b8-29ef-708e-ada4-cb8260fa5139", "version": 1, "description": null }, "evidence": "Slides 6-19 present the company's vision and growth opportunities", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 20, "type": "appendix", "title": "Slide 20 of the presentation.", "function": "other", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "dense", "densityScore": 67, "componentCount": 9, "textChars": 318, "nDataPoints": 0, "notes": "Slide 20 of the presentation.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:40.39+00", "seconds": 7.401, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/20", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-20", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.133, "w": 0.133, "x": 0.818, "y": 0.581 }, "kind": "image", "text": "Richard A. Graham", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:40.39+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6cd91ab6-fb5e-4b5b-a8da-332e9c96df5a", "parentComponentId": null }, { "bbox": { "h": 0.133, "w": 0.133, "x": 0.818, "y": 0.262 }, "kind": "image", "text": "Rhonda F. Farnum", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:40.39+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8746a5e6-906b-488d-93ed-5c4cc3484a9a", "parentComponentId": null }, { "bbox": { "h": 0.133, "w": 0.133, "x": 0.318, "y": 0.581 }, "kind": "image", "text": "Aziz Sawaf", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:40.39+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d816683b-d716-4ae9-a010-c47018ba499a", "parentComponentId": null }, { "bbox": { "h": 0.133, "w": 0.133, "x": 0.318, "y": 0.262 }, "kind": "image", "text": "Rick E Winningham", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:40.39+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f78d52c5-7436-42bb-bbed-c2a8cfe2dfc1", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.15, "x": 0.154, "y": 0.593 }, "kind": "paragraph", "text": "Aziz Sawaf, CFA, Senior Vice President, Chief Financial Officer", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:40.39+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "98667a13-b4d7-426b-907f-e59b4ce508e7", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.554, "y": 0.293 }, "kind": "paragraph", "text": "Rhonda F. Farnum, Senior Vice President, Chief Business Officer", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:40.39+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b476b5da-fa1e-435c-b257-d28ab52d72e8", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.054, "y": 0.305 }, "kind": "paragraph", "text": "Rick E Winningham, Chairman and Chief Executive Officer", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:40.39+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e1df9e73-0f41-416f-abd1-b88253145fee", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.554, "y": 0.571 }, "kind": "paragraph", "text": "Richard A. Graham, Senior Vice President, Research and Development", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:40.39+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ea5caea8-4501-427c-8af0-cc308ae89728", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.25, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "Q&A Session", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:40.39+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2051233e-97cb-44e8-b97f-5be6977b388c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 25, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 20, "name": "The Bridge", "beatId": "a787cdd9-f5b1-4924-8826-e957eaed06be", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "The Bridge", "slug": "transformation-tale-the-bridge", "status": "active", "canonId": "019dd9b8-2a87-70ce-999e-f64c0e545f5d", "version": 1, "description": null }, "evidence": "Slides 20-25 provide a bridge between the current state and future vision", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 21, "type": "setup", "title": "Standard pharmaceutical product disclosure slide.", "function": "other", "rawType": "appendix_disclosure", "block": null, "metadata": { "slideType": "appendix_disclosure", "slideTypeCanon": { "name": "Appendix disclosure", "slug": "appendix_disclosure", "status": "active", "canonId": "019de52d-07b2-7549-8e8b-932a19f6e616", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 23, "componentCount": 3, "textChars": 258, "nDataPoints": 0, "notes": "Standard pharmaceutical product disclosure slide.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:35.091+00", "seconds": 2.045, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/21", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-21", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "paragraph", "text": "YUPELRI® inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Important Safety Information (US)...", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.091+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f05a6f1f-94d0-4357-ad11-a499ad6957a8", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.3, "x": 0.14, "y": 0.91 }, "kind": "source-note", "text": "OATP, organic anion transporting polypeptide.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.091+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bbeef980-e9f4-4120-8c01-989f89291ffd", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "YUPELRI® (revefenacin) inhalation solution", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.091+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dd1c02eb-f5d5-48bc-ae41-9558f373d39b", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 25, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 20, "name": "The Bridge", "beatId": "a787cdd9-f5b1-4924-8826-e957eaed06be", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "The Bridge", "slug": "transformation-tale-the-bridge", "status": "active", "canonId": "019dd9b8-2a87-70ce-999e-f64c0e545f5d", "version": 1, "description": null }, "evidence": "Slides 20-25 provide a bridge between the current state and future vision", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 22, "type": "appendix", "title": "Includes a footnote regarding market research methodology.", "function": "establish_context", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "dense", "densityScore": 57, "componentCount": 4, "textChars": 876, "nDataPoints": 1, "notes": "Includes a footnote regarding market research methodology.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:36.357+00", "seconds": 3.253, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/22", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-22", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.32 }, "kind": "paragraph", "text": "Market research by Theravance Biopharma indicates approximately 9% of the treated COPD patients in the US use nebulizers for ongoing maintenance therapy.1 LAMAs are a cornerstone of maintenance therapy for COPD and YUPELRI® is positioned as the first once-daily single-agent bronchodilator product for COPD patients who require, or prefer, nebulized therapy. YUPELRI®'s stability in both metered dose inhaler and dry powder device formulations suggest that this LAMA could also serve as a foundation for novel handheld combination products.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.357+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1f3f5de7-b108-43e8-91dc-cad2ed3b8734", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.24 }, "kind": "paragraph", "text": "YUPELRI® (revefenacin) inhalation solution is a once-daily nebulized LAMA approved for the maintenance treatment of COPD in the US.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.357+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c0b6feda-3054-4224-a10b-64650ba8ba14", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.14, "y": 0.9 }, "kind": "source-note", "text": "1. TBPH market research (N=160 physicians); refers to US COPD patients. COPD, chronic obstructive pulmonary disease; LAMA, long-acting muscarinic antagonist.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.357+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "86a7a5a5-b364-4231-8af2-463958ab4078", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "About YUPELRI® (revefenacin) Inhalation Solution", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.357+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a5501eef-bd5f-4843-9302-6514c5eae1d4", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 25, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 20, "name": "The Bridge", "beatId": "a787cdd9-f5b1-4924-8826-e957eaed06be", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "The Bridge", "slug": "transformation-tale-the-bridge", "status": "active", "canonId": "019dd9b8-2a87-70ce-999e-f64c0e545f5d", "version": 1, "description": null }, "evidence": "Slides 20-25 provide a bridge between the current state and future vision", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 23, "type": "appendix", "function": "appendix", "rawType": "appendix", "block": null, "metadata": { "slideType": "appendix", "slideTypeCanon": { "name": "Appendix", "slug": "appendix", "status": "active", "canonId": "019de52d-0762-71f8-b564-89ab863301cc", "version": 1, "description": null }, "function": "appendix", "functionCanon": { "name": "Appendix", "slug": "appendix", "status": "active", "canonId": "019de52d-138d-750b-83c3-49b4bc7a7a38", "version": 1, "description": null }, "density": "sparse", "densityScore": 6, "componentCount": 2, "textChars": 61, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:35.211+00", "seconds": 1.993, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/23", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-23", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.35, "x": 0.08, "y": 0.14 }, "kind": "image", "text": "Theravance Biopharma Medicines That Make a Difference", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.211+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aede086b-2c70-4d53-9682-554735a24823", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.15, "x": 0.08, "y": 0.52 }, "kind": "title", "text": "Appendix", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:35.211+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fd449a84-4add-4109-968b-688b4e88aa26", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 25, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 20, "name": "The Bridge", "beatId": "a787cdd9-f5b1-4924-8826-e957eaed06be", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "The Bridge", "slug": "transformation-tale-the-bridge", "status": "active", "canonId": "019dd9b8-2a87-70ce-999e-f64c0e545f5d", "version": 1, "description": null }, "evidence": "Slides 20-25 provide a bridge between the current state and future vision", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 24, "type": "setup", "function": "introduce_nominees", "rawType": "nominee_bio", "block": null, "metadata": { "slideType": "nominee_bio", "slideTypeCanon": { "name": "Nominee bio", "slug": "nominee_bio", "status": "active", "canonId": "019de52d-1136-70ae-861a-f546f0c9d1ef", "version": 1, "description": null }, "function": "introduce_nominees", "functionCanon": { "name": "Introduce nominees", "slug": "introduce_nominees", "status": "active", "canonId": "019de52d-1833-77fe-ac47-5f26d823a84a", "version": 1, "description": null }, "density": "balanced", "densityScore": 44, "componentCount": 3, "textChars": 1016, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:39.47+00", "seconds": 6.093, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/24", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-24", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.22, "x": 0.05, "y": 0.23 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:39.47+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4a36ea70-18a5-4cd5-b821-8a1b2981f345", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.66, "x": 0.29, "y": 0.23 }, "kind": "paragraph", "text": "Susannah Gray served as the Executive Vice President and Chief Financial Officer of Royalty Pharma, the largest aggregator of pharmaceutical royalty interests worldwide, from January 2005 to December 2018. She was promoted to Executive Vice President of Finance and Strategy in December 2018 and retired from Royalty Pharma in September 2019. Prior to Royalty Pharma, Ms. Gray served as a managing director and senior analyst covering the healthcare sector in CIBC World Markets’ high yield group from 2002 to 2004, and also previously served in similar roles at Merrill Lynch and Chase Securities (predecessor of J.P. Morgan Securities). She currently serves on the Boards of Directors of Maravai LifeSciences, 4D Molecular Therapeutics and Morphic Therapeutic. Previously, Ms. Gray served on the Board of Directors of Apria until its sale to Owens & Minor. Ms. Gray received a BA, with honors, from Wesleyan University and an MBA from Columbia University.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:39.47+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d1b1e7d3-eb18-4fee-9680-0dad0547d2ef", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.6, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Appoints Susannah Gray to Board as new Independent Director", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:39.47+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b0c39003-a92e-46db-b2d3-f5ca3b90e71e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 25, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 20, "name": "The Bridge", "beatId": "a787cdd9-f5b1-4924-8826-e957eaed06be", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "The Bridge", "slug": "transformation-tale-the-bridge", "status": "active", "canonId": "019dd9b8-2a87-70ce-999e-f64c0e545f5d", "version": 1, "description": null }, "evidence": "Slides 20-25 provide a bridge between the current state and future vision", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 25, "type": "setup", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 5, "textChars": 792, "nDataPoints": 6, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:36.286+00", "seconds": 2.669, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/25", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-25", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.9 }, "kind": "disclaimer", "text": "1. Year-to-date through Q4’22; 2. Data from MSA patients at week 6... 3. Biaggioni I, et al. Abstract 34... MSA, multiple system atrophy; OHSA, orthostatic hypotension symptom assessment; PIFR, peak inspiratory flow rate.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.286+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b3302020-86e0-4a0a-bebc-7263a11dc7fb", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.28, "x": 0.67, "y": 0.25 }, "kind": "list", "text": "Financial: Sold TRELEGY ELLIPTA royalty interests for $1.1B upfront; Eliminated all debt, ~$650 million; Completed financial restructuring; Initiated $250 million capital return program", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.286+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2b26f82e-968c-4209-a32b-ef3bb6bcf700", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.28, "x": 0.36, "y": 0.25 }, "kind": "list", "text": "Ampreloxetine: Prevented blood pressure drop in MSA; Aligned with FDA on Phase 3 study; Three scientific platform presentations; Secured up to $40 million from Royalty Pharma", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.286+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3f59c7d2-e03e-48bb-bfed-e1c8e21d918a", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.28, "x": 0.05, "y": 0.25 }, "kind": "list", "text": "YUPELRI: Three consecutive quarters of all-time high Net Sales and Profit in Q2-Q4; Continued community market share growth; 53% Y/Y growth in hospital volume; Initiated PIFR-2 study", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.286+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "68384a76-0286-4570-bec9-b1832c3a5f2a", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.4, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "2022: A Year of Transformation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.286+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6198a648-1886-4e15-8ea4-b4d56cf4245b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "148dbfb1-622b-4ed8-a452-58aae51d61fe", "evidence": "2022: A Year of Transformation", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:19:46.148579+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 25, "arc": { "name": "The Transformation Tale", "slug": "transformation-tale", "status": "active", "bestFor": "Sales presentations, product launches, fundraising", "canonId": "019dd956-6128-70fa-9bff-ab3c0b4ad09f", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Current Reality (Pain) -> Future Vision (Gain) -> The Bridge", "description": null, "familyLabel": null }, "from": 20, "name": "The Bridge", "beatId": "a787cdd9-f5b1-4924-8826-e957eaed06be", "matchId": "89fd8ce5-1a8a-42e3-b948-5f57d6348efe", "beatType": { "name": "The Bridge", "slug": "transformation-tale-the-bridge", "status": "active", "canonId": "019dd9b8-2a87-70ce-999e-f64c0e545f5d", "version": 1, "description": null }, "evidence": "Slides 20-25 provide a bridge between the current state and future vision", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 26, "type": "analysis", "title": "Includes abbreviations for COPD, nOH, and PTE in the footer.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 3, "textChars": 538, "nDataPoints": 5, "notes": "Includes abbreviations for COPD, nOH, and PTE in the footer.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:36.494+00", "seconds": 2.794, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/26", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-26", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.6, "x": 0.13, "y": 0.91 }, "kind": "subtitle", "text": "COPD, Chronic obstructive pulmonary disease; nOH, neurogenic orthostatic hypotension; PTE, patent term extensions.", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c77a9ec9-eeac-4512-9f2a-4458cb8f2929", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.84, "x": 0.08, "y": 0.21 }, "kind": "table", "text": "Compound, Invention, Granted / Pending Application, Estimated Patent Expiry; YUPELRI / revefenacin, Composition of Matter, Granted US, 2028 (once PTE awarded); Polymorph, Granted US, 2030-2031; Method for the maintenance treatment of COPD patients, Granted US, 2039; Ampreloxetine, Composition of Matter, Granted US, 2030 (plus PTE of up to 5 years); Method of Treating nOH, Granted US, 2037", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e1f26a2f-87d6-4c82-9eba-50ef484baf0a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "Patent Protection Into Late 2030s", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.494+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c95b4f39-9afb-4bfb-9145-1ecc518e4144", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 27, "type": "resolution", "title": "The funnel visualizes the drop-off from total diagnosed COPD patients to those currently on YUPELRI.", "function": "size_opportunity", "rawType": "customer_journey", "block": null, "metadata": { "slideType": "customer_journey", "slideTypeCanon": { "name": "Customer journey", "slug": "customer_journey", "status": "active", "canonId": "019de52d-0966-70ce-afe3-bc7c98ffc8c9", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 85, "componentCount": 7, "textChars": 1096, "nDataPoints": 8, "notes": "The funnel visualizes the drop-off from total diagnosed COPD patients to those currently on YUPELRI.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:42.45+00", "seconds": 8.723, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/27", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-27", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.38, "x": 0.04, "y": 0.215 }, "kind": "chart", "text": "Estimated 2021 YUPELRI Patient Funnel (US)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Funnel", "slug": "funnel", "status": "active", "canonId": "019de52d-02ae-73f8-9daa-84dddccbc459", "version": 1, "description": null }, "framework": null }, "subkind": "funnel", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:42.45+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1eda45eb-c1b8-44c9-8209-4948bc1b1581", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.96, "x": 0.02, "y": 0.91 }, "kind": "disclaimer", "text": "1. American Lung Association. 2. Clarivate COPD Disease Landscape & Forecast US 2021. 3. Revefenacin COPD Joint Venture Research 2016. 4. Safka KA, et al. Chronic Obstr Pulm Dis 2017. 5. Mahler DA, et al. Chronic Obstr Pulm Dis 2019. 6. Armitage JM, Williams SJ Inhaler technique in the elderly. Age Ageing 1988 17:275-278. COPD, chronic obstructive pulmonary disease; DME, durable medical equipment; LAMA, long-acting muscarinic antagonist; PIFR, peak inspiratory flow rate.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:42.45+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b4a440ad-476e-4126-b5f6-33c840be559d", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.55, "x": 0.41, "y": 0.42 }, "kind": "framework", "text": "Growth opportunities within numerous patient segments", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:42.45+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "508dfbcd-6e11-4043-ad1f-d531330b4c5d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.52, "x": 0.44, "y": 0.21 }, "kind": "list", "text": "COPD is under-diagnosed; COPD patients with or without symptoms may be treated with rescue and/or maintenance therapies; Estimated patient counts from volume using average 'days of therapy' assumptions vary considerably across DME and retail channels", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:42.45+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d3ca2d04-05a5-448b-a074-708898045435", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.38, "x": 0.04, "y": 0.78 }, "kind": "source-note", "text": "Patent No 11,484,531, methods of treating COPD, expiring in 2039, is now listed in the Approved Drug Products with Therapeutic Equivalence Evaluations", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:42.45+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "903cebee-edc5-4085-a3f3-4092f609ba36", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.92, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "Substantial Opportunity for Further YUPELRI® Growth", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:42.45+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "085c2dc5-1716-4a07-a0ba-844e8da4706c", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.78, "x": 0.04, "y": 0.13 }, "kind": "title", "text": "Once-Daily Nebulized LAMA COPD treatment represents a sizeable niche market", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:42.45+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c1cde3f5-4479-449c-8003-389ba9a7077f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "c3e57869-e581-4b4a-a256-c08ece204561", "evidence": "The slide uses a funnel to represent the patient journey from diagnosis to treatment, followed by specific segment opportunities.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:06:42.45+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "frameworkName": "customer-journey-map" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 28, "type": "appendix", "title": "Slide lists specific academic abstracts presented at the 33rd International Symposium on the Autonomic Nervous System.", "function": "other", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 77, "componentCount": 7, "textChars": 807, "nDataPoints": 0, "notes": "Slide lists specific academic abstracts presented at the 33rd International Symposium on the Autonomic Nervous System.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:36.825+00", "seconds": 2.901, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/28", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-28", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.4, "x": 0.14, "y": 0.91 }, "kind": "disclaimer", "text": "MSA, multiple system atrophy; nOH, neurogenic orthostatic hypotension.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.825+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "495f1816-1c09-4d1a-ad31-0f8fc2ac47fe", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.07, "y": 0.25 }, "kind": "image", "text": "American Autonomic Society logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.825+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1ed3ff81-3d54-47fb-90c9-0c1648aae60e", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.85, "x": 0.07, "y": 0.56 }, "kind": "list", "text": "Kaufmann H, et al. Abstract 33 / Virtual Poster 117. Blood pressure and pharmacodynamic response of ampreloxetine, a norepinephrine reuptake inhibitor, in patients with symptomatic nOH", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.825+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12e6f3c2-ee4d-4c50-ac90-1b72ed8155d6", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.85, "x": 0.07, "y": 0.72 }, "kind": "list", "text": "Freeman R, et al. Abstract 30 / Virtual Poster 4. Longitudinal analysis of ampreloxetine for the treatment of symptomatic nOH in subset of patients with MSA", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.825+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2d5bc670-5488-42a6-b3ff-f0076a94ebd4", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.85, "x": 0.07, "y": 0.4 }, "kind": "list", "text": "Platform Presentations, Session 1, November 2, 2022. Biaggioni I, et al. Abstract 34 / Virtual Poster 106. A phase 3, 22-week, multi-center, randomized withdrawal study of ampreloxetine in treating symptomatic nOH.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.825+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af0ad6c1-8da5-44a4-87a6-5557c01baeb4", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.5, "x": 0.38, "y": 0.27 }, "kind": "paragraph", "text": "33rd International Symposium on the Autonomic Nervous System November 2–5, 2022: Sheraton Maui, Hawaii", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.825+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "84de131b-2b27-4da2-b331-9d33ff0571a5", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.9, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "Offering Hope to MSA Patients with Symptomatic nOH", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:36.825+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ce809998-4fac-4ed4-bb5e-d0d7d1624b8e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 29, "type": "evidence", "title": "The slide uses a before-after framework to justify a strategic pivot in clinical trial focus.", "function": "present_solution", "rawType": "before_after", "block": null, "metadata": { "slideType": "before_after", "slideTypeCanon": { "name": "Before / after", "slug": "before_after", "status": "active", "canonId": "019de52d-11fd-771e-bb45-e27f849bc560", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 86, "componentCount": 8, "textChars": 658, "nDataPoints": 24, "notes": "The slide uses a before-after framework to justify a strategic pivot in clinical trial focus.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:49.826+00", "seconds": 15.688, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/29", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-29", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.3, "x": 0.29, "y": 0.0055 }, "kind": "chart", "text": "Study 0170 OHQ Questionnaire Scores", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:49.826+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b6996cdc-c258-48b5-8c58-4b1343b6b5d8", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.3, "x": 0.64, "y": 0.0055 }, "kind": "chart", "text": "Durable effectiveness OHSA composite score over time", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:49.826+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f2167762-5408-4951-80da-e5606c99c517", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.05, "y": 0.0025 }, "kind": "chart", "text": "Old program focus areas: PD, PAF, MSA", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Pie chart", "slug": "pie", "status": "active", "canonId": "019de52c-ffdb-71bb-a800-5c5ab9f1c373", "version": 1, "description": null }, "framework": null }, "subkind": "pie", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:49.826+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "638eebbe-c3ef-4a01-8c11-15ce90c54b58", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.7, "y": 0.0022 }, "kind": "list", "text": "In study 0170, ampreloxetine prevented blood pressure drop and symptoms worsening in MSA. Support from scientific community. Aligned with FDA on new Phase 3 study.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:49.826+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3a399c45-d15b-4cc1-bed1-9f69951fc788", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.4, "x": 0.5, "y": 0.0018 }, "kind": "paragraph", "text": "\"New\" MSA-focused Ampreloxetine Program", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:49.826+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "076b6811-6684-4d7e-ba35-4b38dcad6440", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.25, "x": 0.03, "y": 0.0018 }, "kind": "paragraph", "text": "\"Old\" Ampreloxetine Program", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:49.826+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f4f8ebd0-60e5-4ea5-83b9-015c006f8111", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.94, "x": 0.03, "y": 0.9 }, "kind": "source-note", "text": "1. Data from MSA patients at week 6 of the randomized withdrawal period of study 0170. 2. Biaggioni I, et al. Abstract 34 / Virtual Poster 106; Kaufmann H, et al. Abstract 33 / Virtual Poster 117; Freeman R, et al. Abstract 30 / Virtual Poster 4.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:49.826+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e5abe2d0-81b5-4c4d-98d5-56a32a3f2048", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.94, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Shift Toward Broad Symptomatic Improvement for MSA Patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:49.826+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2ed3a243-c8b0-4146-a41f-ef0ed40f0540", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "52505bf8-cd47-42c1-ba84-9d77bb58ae2d", "evidence": "Contrasts 'Old' program with 'New' program to show strategic shift.", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:06:49.826+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "frameworkName": "before-after-framing" } ], "arcBeats": [], "loops": [ { "to": 29, "from": 29, "loop": { "name": "21_before_after", "slug": "21-before-after", "status": "active", "bestFor": "Product demos, process improvements, ROI justification", "canonId": "019dd956-6e68-73fd-a295-fe90145c2da8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison", "familyLabel": null }, "matchId": "7826842e-2e9b-4a36-849d-9c76e7c2f257", "evidence": "The before-after slide effectively communicates the benefits of Ampreloxetine treatment", "position": 0, "objective": "Illustrate the potential for broad symptomatic improvement for MSA patients", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:30:23.33131+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 30, "type": "analysis", "title": "Includes a detailed table for Trelegy Ellipta royalties and milestones by year.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 89, "componentCount": 8, "textChars": 839, "nDataPoints": 24, "notes": "Includes a detailed table for Trelegy Ellipta royalties and milestones by year.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:37.503+00", "seconds": 3.271, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/30", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-30", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.4, "x": 0.53, "y": 0.32 }, "kind": "list", "text": "Upfront payment: $25M (Received)\n1st Regulatory approval milestone: $15M\nFuture royalties paid to Royalty Pharma: 2.5% on annual global net sales up to $500M; 4.5% on annual global net sales > $500M", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "24db60ca-24c0-4682-a083-9fb031536b20", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.3, "x": 0.06, "y": 0.3 }, "kind": "list", "text": "Upfront: $1.1B (Received)\nMilestones: Up to $250M", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b02a397d-b5b7-46c7-b367-07b6ec28f582", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.6, "y": 0.24 }, "kind": "paragraph", "text": "Ampreloxetine (Unsecured Royalty)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "13873da4-9c9f-429c-a404-bbfae1db8608", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.25, "x": 0.15, "y": 0.24 }, "kind": "paragraph", "text": "TRELEGY ELLIPTA", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "25cdd43f-40ca-4338-b2b3-220fb6913730", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.06, "y": 0.7 }, "kind": "paragraph", "text": "Outer Year Royalty (\"OYR\"): 85% of royalties for TRELEGY ELLIPTA return to Theravance Biopharma: On and after January 1, 2031 for U.S. sales; On and after July 1, 2029 for ex-U.S. sales", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "46888430-b700-49bc-9826-0015fcf0cfcb", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.9 }, "kind": "source-note", "text": "1. If both milestones are achieved in a given year, Theravance Biopharma will only earn the higher milestone. 2. Based on 100% of TRELEGY ELLIPTA royalties. 3. U.S. royalties expected to end late 2032; ex-U.S. royalties expected to end mid-2030s.", "attrs": { "numbered": true }, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c6535291-ade5-40c9-be6d-9bea7e6fc77b", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.35, "x": 0.11, "y": 0.38 }, "kind": "table", "text": "Year, Royalties, Global Net Sales Equivalent, Milestone table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c032ca5a-b5ab-4472-80a1-f9816c71d97c", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Theravance Biopharma and Royalty Pharma Deal Summary", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.503+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10968461-c9bc-4358-823e-ab6923b03090", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 31, "type": "analysis", "title": "Includes cash position, income statement items, and adjusted operating expenses excluding share-based compensation.", "function": "analyze_data", "rawType": "kpi_overview", "block": null, "metadata": { "slideType": "kpi_overview", "slideTypeCanon": { "name": "KPI overview (contrarian)", "slug": "kpi_overview", "status": "active", "canonId": "019de52d-11d5-7328-b1d1-5368a03e7796", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 4, "textChars": 247, "nDataPoints": 64, "notes": "Includes cash position, income statement items, and adjusted operating expenses excluding share-based compensation.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:06:37.169+00", "seconds": 2.878, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de074-6c10-759a-a503-c8b869115e9a/31", "deck": "/decks/019de074-6c10-759a-a503-c8b869115e9a", "deckAnchor": "/decks/019de074-6c10-759a-a503-c8b869115e9a#slide-31", "deckJson": "/decks/019de074-6c10-759a-a503-c8b869115e9a.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.4, "x": 0.05, "y": 0.91 }, "kind": "source-note", "text": "1. Cash, cash equivalents and marketable securities. 2. Amounts include share-based compensation.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "12dad3b7-3df3-4823-9c24-8b9c0a6016a7", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.05, "y": 0.13 }, "kind": "subtitle", "text": "$327.5 million cash1 as of December 31, 2022", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2e1b9768-0781-41a9-be0f-c7fbcebfd662", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.9, "x": 0.05, "y": 0.18 }, "kind": "table", "text": "Financial statement table with columns for 3 months and year ended 2022/2021", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "31b0c2e7-8cad-4e61-9071-e64dd859c67f", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.5, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Fourth Quarter 2022 Financials", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:06:37.169+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1db3fc07-afc1-4c06-b813-cd391e32af06", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 1, "to": 5, "label": "Current Reality (Pain)", "description": "Slides 1-5 set the stage for Theravance Biopharma's current state and challenges" }, { "from": 6, "to": 19, "label": "Future Vision (Gain)", "description": "Slides 6-19 present the company's vision and growth opportunities" }, { "from": 20, "to": 25, "label": "The Bridge", "description": "Slides 20-25 provide a bridge between the current state and future vision" } ], "loops": [ { "from": 29, "to": 29, "label": "Before After", "description": "Illustrate the potential for broad symptomatic improvement for MSA patients" }, { "from": 7, "to": 7, "label": "Quick Win Big Bet", "description": "Highlight YUPELRI's growing net sales and hospital volume as a quick win" } ] }